Patient‐reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer

Abstract

Background To the authors' knowledge, it is unknown whether patient‐reported symptom severity and symptom interference with daily activities differ between younger (aged <65 years) and older (aged ≥65 years) women receiving similar chemotherapy regimens for early breast cancer (EBC). Methods Study participants rated 17 side effects of chemotherapy regimens currently in use in clinical practice (2014‐2019). Results Of 284 women with EBC (stage I‐III), approximately 57% were aged <65 years and 43% were aged ≥65 years. For anthracycline‐based regimens, a higher percentage of younger women reported moderate, severe, or very severe (MSVS) hot flashes (49% vs 18%) (P < .001). For nonanthracycline regimens, a higher percentage of younger women reported MSVS hot flashes (38% vs 19%) (P = .009) and a lower percentage reported MSVS arthralgia (28% vs 49%) (P = .005). With regard to symptom interference with daily activities, a higher percentage of younger women being treated with anthracycline‐based regimens reported MSVS hot flashes (32% vs 7%) (P = .001) and myalgia (38% vs 18%) (P = .02). For nonanthracycline chemotherapy, a higher percentage of younger women reported MSVS interference for hot flashes (26% vs 9%) (P = .006) and lower percentages reported abdominal pain (13% vs 28%) (P = .02). Overall, there were no significant differences noted among younger versus older patients with regard to hospitalizations (19% vs 12%; P = .19), dose reductions (34% vs 31%; P = .50), dose delays (22% vs 25%; P = .59), or early treatment discontinuation (16% vs 16%; P = .9546). Conclusions Older and younger women with EBC who were treated with identical chemotherapy regimens generally experienced similar levels of symptom severity, symptom‐related interference with daily activities, and adverse events. Lay Summary In this study, women receiving chemotherapy for early breast cancer rated the severity of 17 symptoms and symptom interference with their activities of daily living. Older (aged ≥65 years) and younger (aged <65 years) women who received identical chemotherapy regimens generally experienced similar levels of symptom severity, symptom‐related interference with daily activities, and adverse events.

Symptom burden, psychological distress, and symptom management status in hospitalized patients with advanced cancer: a multicenter study in China

“…Another possible reason is the treatment-related side effects brought by the anticancer treatment itself. Previous studies found that the treatment adverse reactions are also a major source of symptom burden, 30 , 31 , 32 especially the burden of somatic symptoms.…”

Social Vulnerability Index Contributes to Patient History: Women Treated with Chemotherapy for Early-Stage Breast Cancer

“…All of these variables provide a context for the observed associations of SVI with symptom experience prior to chemotherapy and during chemotherapy, as well as how these symptoms interfere with the patient's activities of daily living. These SVI ndings provide added context to our prior studies in which we have reported symptom experiences between patient with high as compared to normal BMI [34], Black and White patients[8], and younger as compared to older patients [35]. SVI adds geography to the patient pro le.…”

“…Both formats inquire about symptom "severity" and "interference with daily activities" with response options none, mild, moderate, severe or very severe. Data collected from both instruments have been combined, as in our previous studies [9,[30][31][32].…”

“…The pooled data enabled us to have the largest possible sample size and power to analyze potential differences between younger and older patients. Protocols were identical between all three studies, as described in previous publications [8,9]. Studies were approved by the UNC Institutional Review Board and the UNC Lineberger Comprehensive Cancer Center Protocol Review Committee.…”

Perspectives and Experiences of Healthcare Professionals Involved in a Community Nurse-Delivered Shared Care Model Intervention Designed to Support Outpatients Receiving Chemotherapy: A Qualitative Study Using Interviews

“…In Australia, systemic cancer treatment, including chemotherapy, was administered to 247,939 patients in 2016, representing a 25% increase since 2012 [1]. Chemotherapy frequently causes physical side efects [2], with more than 75% of Australians undergoing chemotherapy for cancer reporting multiple moderate or severe side efects [3]. Individuals with cancer also commonly experience psychosocial and emotional challenges during treatment [4,5].…”